GILADAFINS (GILADAFINS) Fair Value & Analysis
IN · Market cap ₹194M
Fair value as of: Jul 5, 2026
From 24 valuation models · updated today
Share price +17.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹11.38 – ₹21.76 · fair‑value band ₹19.42 – ₹25.25 · the ₹13.84 price screens below the ₹19.42 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
GILADAFINS (GILADAFINS) currently trades at ₹13.84, while our model-based Fair Value estimate is ₹19.42 — implying the stock looks roughly 40.3% undervalued today. We read business quality at 51/100 (solid quality). Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Net debt stands at ₹104M. The stock trades on a trailing P/E of 8.9. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹19.42 (bear case) to ₹25.25 (bull case); at ₹13.84, the current price sits below that range. The share trades about 42% below its 52-week high and 29% above its 52-week low, currently above its 200-day average.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
GILADAFINS reported revenue of ₹72.6M in FY2026 versus ₹37.5M in FY2022, a compound +17.9%/yr. Reported net income was ₹21.7M in FY2026, compounding +13.1%/yr from FY2022.
Is GILADAFINS fairly valued? → Check now
Explore undervalued stocks
Frequently asked questions
Is GILADAFINS (GILADAFINS) undervalued?
What is the fair value of GILADAFINS?
What is the quality score of GILADAFINS?
What is the net profit margin of GILADAFINS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.